Clinuvel Pharmaceuticals (CLVLF) Stock Forecast & Price Target

Compare

44 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CLVLF Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Clinuvel

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CLVLF Stock 12 Month Forecast

Average Price Target

$15.51

▲(114.52% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Clinuvel Pharmaceuticals in the last 3 months. The average price target is $15.51 with a high forecast of $21.74 and a low forecast of $9.27. The average price target represents a 114.52% change from the last price of $7.23.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","9.25":"$9.25","13.5":"$13.5","17.75":"$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.96,8.096923076923076,9.233846153846153,10.37076923076923,11.507692307692306,12.644615384615385,13.78153846153846,14.918461538461536,16.055384615384614,17.19230769230769,18.32923076923077,19.466153846153844,20.60307692307692,{"y":21.74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.96,7.617692307692308,8.275384615384615,8.933076923076923,9.590769230769231,10.24846153846154,10.906153846153847,11.563846153846153,12.221538461538461,12.87923076923077,13.536923076923078,14.194615384615386,14.852307692307694,{"y":15.51,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.96,7.137692307692308,7.315384615384615,7.493076923076923,7.67076923076923,7.848461538461538,8.026153846153846,8.203846153846154,8.381538461538462,8.55923076923077,8.736923076923077,8.914615384615384,9.092307692307692,{"y":9.27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.51,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.74

Average Price Target$15.51

Lowest Price Target$9.27

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Iain Wilkie

Morgans

$9.28

Buy

28.41%

Upside

Upgraded

11/11/25

Clinuvel Pharmaceuticals (CLVLF) was upgraded to a Buy Rating at Morgans

Madeleine Williams

Canaccord Genuity

$21.78

Buy

201.21%

Upside

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: Polynovo (Other OTC: CALZF) and Clinuvel Pharmaceuticals (Other OTC: CLVLF)

Sinclair Currie

MA Financial Group

$15.34

Buy

112.15%

Upside

Reiterated

08/29/25

Thomas Wakim

Bell Potter

$12.6

Buy

74.27%

Upside

Reiterated

08/29/25

Bell Potter Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

David Stanton

Jefferies

$26.53

Buy

266.89%

Upside

Reiterated

07/18/25

Jefferies Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$14.99

Buy

107.29%

Upside

Reiterated

07/01/25

Ord Minnett Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Iain Wilkie

Morgans

$9.28

Buy

28.41%

Upside

Upgraded

11/11/25

Clinuvel Pharmaceuticals (CLVLF) was upgraded to a Buy Rating at Morgans

Madeleine Williams

Canaccord Genuity

$21.78

Buy

201.21%

Upside

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: Polynovo (Other OTC: CALZF) and Clinuvel Pharmaceuticals (Other OTC: CLVLF)

Sinclair Currie

MA Financial Group

$15.34

Buy

112.15%

Upside

Reiterated

08/29/25

Thomas Wakim

Bell Potter

$12.6

Buy

74.27%

Upside

Reiterated

08/29/25

Bell Potter Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

David Stanton

Jefferies

$26.53

Buy

266.89%

Upside

Reiterated

07/18/25

Jefferies Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$14.99

Buy

107.29%

Upside

Reiterated

07/01/25

Ord Minnett Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Clinuvel Pharmaceuticals

1 Month

xxx

Success Rate

1/3 ratings generated profit

Average Return

-0.93%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -0.93% per trade.

3 Months

xxx

Success Rate

2/8 ratings generated profit

Average Return

-7.19%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -7.19% per trade.

1 Year

David StantonJefferies

Success Rate

3/8 ratings generated profit

Average Return

-13.41%

reiterated a buy rating 5 months ago

Copying David Stanton's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -13.41% per trade.

2 Years

xxx

Success Rate

3/8 ratings generated profit

Average Return

-12.14%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -12.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLVLF Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CLVLF has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLVLF average Analyst price target in the past 3 months is 15.51.

Each month's total comprises the sum of three months' worth of ratings.

CLVLF Financial Forecast

CLVLF Earnings Forecast

Next quarter’s earnings estimate for CLVLF is $0.18 with a range of $0.18 to $0.18. The previous quarter’s EPS was $0.29. CLVLF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CLVLF has Performed in-line its overall industry.

CLVLF Sales Forecast

Next quarter’s sales forecast for CLVLF is $25.79M with a range of $25.79M to $25.79M. The previous quarter’s sales results were $39.62M. CLVLF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CLVLF has Performed in-line its overall industry.

CLVLF Stock Forecast FAQ

What is CLVLF’s average 12-month price target, according to analysts?

Based on analyst ratings, Clinuvel Pharmaceuticals Limited’s 12-month average price target is 15.51.

What is CLVLF’s upside potential, based on the analysts’ average price target?

Clinuvel Pharmaceuticals Limited has 114.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CLVLF a Buy, Sell or Hold?

Clinuvel Pharmaceuticals Limited has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Clinuvel Pharmaceuticals Limited’s price target?

The average price target for Clinuvel Pharmaceuticals Limited is 15.51. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.74 ,the lowest forecast is $9.27. The average price target represents 114.52% Increase from the current price of $7.23.

What do analysts say about Clinuvel Pharmaceuticals Limited?

Clinuvel Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of CLVLF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Clinuvel Pharmaceuticals (CLVLF) Stock Forecast & Price Target

CLVLF Analyst Ratings

CLVLF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Clinuvel Pharmaceuticals

CLVLF Analyst Recommendation Trends

CLVLF Financial Forecast

CLVLF Earnings Forecast

CLVLF Sales Forecast

CLVLF Stock Forecast FAQ

Detailed List of Analyst Forecasts